Answers are grounded in this paper and cite their sources.
Differences in reported urinary NGAL levels across previous studies are attributable to the use of different measurement techniques (immunoblotting vs ELISA), which are strongly correlated.
To the Editor: In a previous study, we detected increased urinary neutrophil gelatinase- associated lipocalin (NGAL) levels in patients undergoing cardiac surgery and anesthesia who eventually developed acute renal dysfunction,1 whereas in a second study, we showed a positive correlation between urinary NGAL and aprotinin.2 We wish, however, to clarify an issue raised by McEvoy et al. who, in a recent review,3 pointed out that NGAL levels in the aprotinin study were lower than in the study correlating urinary NGAL with renal dysfunction after cardiac surgery and anesthesia. In our initial study,1 we measured urinary NGAL with semiquantitative immunoblotting technique, whereas in the subsequent study regarding the association of urinary NGAL and aprotinin,2 we used a commercially available and more quantitative enzyme-linked immunosorbent assay (ELISA) kit for the detection of NGAL. When measuring the urinary NGAL with both techniques in 396 samples, we found that NGAL levels measured with immunoblotting technique were on average 2.7 times higher than those measured with ELISA. However, there was a strong positive correlation between the two methods. [Spearman r = 0.776; 95% CI = 0.732–0.813; P < 0.0001)]. Unfortunately, ELISA was not commercially available when we were performing the initial study. In our second study, the mean urinary NGAL levels of patients who received aprotinin were approximately the same as the mean urinary NGAL levels of patients who later developed acute renal dysfunction. For example 3 h after cardiopulmonary bypass, mean NGAL in the aprotinin group was 2006 ± 114 ng/mL and in the group with acute renal dysfunction 1640 ± 117 ng/mL (ns). We would like to also postulate on a possible mechanism of exacerbated renal injury by aprotinin not mentioned in the review by McEvoy et al.3 It is well-known that aprotinin inhibits plasma and tissue kallikrein and kinin cascade in vitro as well as in vivo as McEvoy et al. reference in their review. Several animal studies have shown that kinins and kallikrein system plays a crucial role in protecting the kidney after renal insult including ischemia reperfusion injury.4–6 Inhibition of kinin and kallikrein cascade by aprotinin may reduce the kidney's endogenous protective mechanism and amplify renal injury during cardiopulmonary bypass. Gebhard Wagener, MD H. Thomas Lee, MD, PhD Department of Anesthesiology College of Physicians and Surgeons Columbia University New York City, New York [email protected]
No takes yet. Share an insight, caveat, or question.
Wagener et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: